Goldman Sachs starts coverage on Regeneron Pharma (REGN+0.7%) with a Buy and $144 price target, propelled by its Eylea drug for various eye diseases that lead to vision loss. The firm anticipates "continued robust uptake of Eylea (GS WW peak sales of $4B, $2.3B in U.S.), which we project will propel the company to sustainable profitability in 4Q12."